Saxol Secures $1.5M to Pioneer Next-Generation Neuroprotective Treatments for Peripheral Neuropathies

Saxol, a dynamic new company at the forefront of neurological research, is thrilled to announce a successful funding round that raised 1,500,000 dollars.

This significant investment underscores the confidence that investors have in our innovative approach to tackling peripheral neuropathies, including those associated with diabetes, as well as immuno and chemotherapy-induced conditions (CIPN).

Founded on the groundbreaking insights from IAB research on the Carbazole structure by the Lafanechère Team and further supported by Linksium, Saxol is dedicated to developing neuroprotective compounds that address substantial unmet medical needs.

Our lead compound, CARBA1, has demonstrated promising neuroprotective activity by regulating and reactivating energy production at the cellular level—a critical function in the quest to alleviate nerve damage and pain for patients experiencing CIPN.

The raised funds will primarily support the advancement of CARBA1 through its initial clinical development stages, focusing on its potential use in treating CIPN—a condition that currently lacks effective treatment options.

As part of our long-term strategy, we envision expanding our research to cover additional areas, such as diabetes-induced peripheral neuropathies and other related nerve disorders.

By enhancing our scientific capabilities and accelerating development timelines, this funding marks a pivotal step forward in our mission to transform patient care with innovative and effective neuroprotective drugs.

We are committed to addressing the urgent needs within patients’ lives while driving forward cutting-edge research that paves the way for future medical breakthroughs.